Counselling Framework for Germline BRCA1/2 and PALB2 Carriers Considering Risk-Reducing Mastectomy
Current Oncology · 2024
DOI: 10.3390/curroncol31010023 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, 2024. Verfasst von Stephanie M Wong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, McGill University, Montreal, QC H3G 1A4, Canada. Hauptthemen laut MEDLINE: Mastectomy, Breast Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fonds de Recherche du Québec - Santé, Fonds de Recherche du Quebec Santé.
Abstract (Originalsprache)
Female BRCA1/2 and PALB2 germline pathogenic variant carriers have an increased lifetime risk of breast cancer and may wish to consider risk-reducing mastectomy (RRM) for surgical prevention. Quantifying the residual lifetime risk and absolute benefit from RRM requires careful consideration of a patient’s age, pathogenic variant, and their personal history of breast or ovarian cancer. Historically, patients have been counselled that RRM does not necessarily prolong survival relative to high-risk surveillance, although recent studies suggest a possible survival benefit of RRM in BRCA1 carriers. The uptake of RRM has increased dramatically over the last several decades yet varies according to sociodemographic factors and geographic region. The increased adoption of nipple-sparing mastectomy techniques, ability to avoid axillary staging, and availability of reconstructive options for most germline pathogenic variant carriers has helped to minimize the morbidity of RRM. Preoperative discussions should include evidence regarding postmastectomy sensation, the potential for supplemental surgery, pregnancy-related chest wall changes, and the need for continued clinical surveillance. Approaches that include sensation preservation and robotic nipple-sparing mastectomy are an area of evolving research that may be more widely adopted in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, McGill University, Montreal, QC H3G 1A4, Canada.
- Stroll Cancer Prevention Centre, Sir Mortimer B. Davis Jewish General Hospital, Montreal, QC H3T 1E2, Canada.
- Gerald Bronfman Department of Oncology, McGill University, Montreal, QC H4A 3T2, Canada.
- Department of Human Genetics, McGill University, Montreal, QC H3A 0C7, Canada.
Förderung
- Fonds de Recherche du Québec - Santé
- Fonds de Recherche du Quebec Santé
Zitieren
APA
Wong, S. M., Apostolova, C., Eisenberg, E., & Foulkes, W. D. (2024). Counselling Framework for Germline BRCA1/2 and PALB2 Carriers Considering Risk-Reducing Mastectomy. Current Oncology. https://doi.org/10.3390/curroncol31010023
Vancouver
Wong SM, Apostolova C, Eisenberg E, Foulkes WD. Counselling Framework for Germline BRCA1/2 and PALB2 Carriers Considering Risk-Reducing Mastectomy. Current Oncology. 2024. doi:10.3390/curroncol31010023
BibTeX
@article{Wong2024,
author = {Wong, Stephanie M and Apostolova, Carla and Eisenberg, Elisheva and Foulkes, William D},
title = {Counselling Framework for Germline BRCA1/2 and PALB2 Carriers Considering Risk-Reducing Mastectomy},
journal = {Current Oncology},
year = {2024},
doi = {10.3390/curroncol31010023}
}
EUVIMED